EYE INFLAMMATION TREATMENT MARKET ANALYSIS

Eye Inflammation Treatment MarketSize and Trends

The global eye inflammation treatment market is estimated to be valued at US$ 564.4 Mn in 2022 and is expected to exhibit a CAGR of 5.8% over the forecast period (2022-2030)

Figure 1: Global Eye Inflammation Treatment Market Share, (%), Analysis, By Drug Class,

Global Eye Inflammation Treatment Market Key Drivers

Increasing research and development by key market players for the development of new eye inflammation treatment is expected to drive the growth of global eye inflammation treatment market over the forecast period.

Market players are involved in research and development for the development of eye inflammation treatment is expected to drive the growth of global eye inflammation treatment market. For instance, on April 21, 2022, SALVAT, a manufacturer of sterile liquids pharmaceutical products, completed the phase III clinical trials of its ocular corticosteroid with clobetasol for the treatment of inflammation and pain in cataract surgery patients. To commercialize the new corticosteroid globally in the second half of 2023, the company has started the approval application processes with the U.S. Food and Drug Administration (FDA) and the European health authorities.

Increasing product launch by key market players, for the treatment of eye disease is expected to propel the growth of global eye inflammation treatment market, over the forecast period.

Key market players are launching product for the treatment of eye disease is expected to propel the growth of global eye infection treatment market. For instance, on January 10, 2022, NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, announced the launch of its AVENOVA Lubricant Eye drops. These eye drops are formulated to treat dry eye symptoms. Avenova is antimicrobial and uses pure 0.01% Hypochlorous Acid that fight with toxins and inflammation caused by bacteria.